HIV charities lament NICE snub for Gilead’s twice-yearly lenacapavir
The National Institute for Health and Care Excellence (NICE) has recommended against reimbursement for Gilead’s twice-a-year PrEP medication lenacapavir, prompting…
News
Exegenesis Bio and Modalis sign research deal for Duchenne therapy
ABEC to expand global manufacturing network with new Wilson facility
Encoded secures $275m for Dravet syndrome gene therapy
Bayer’s Hyrnuo set for the NSCLC frontlines on accelerated FDA label expansion
HHS appoints permanent FDA CBER, CDER heads
Solstice Oncology secures $225m to drive porustobart’s development for cancer
TwoStep Therapeutics raises $62.5m in funding to advance TS-104
